1. Home
  2. MGNX vs FTEK Comparison

MGNX vs FTEK Comparison

Compare MGNX & FTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • FTEK
  • Stock Information
  • Founded
  • MGNX 2000
  • FTEK 1987
  • Country
  • MGNX United States
  • FTEK United States
  • Employees
  • MGNX N/A
  • FTEK N/A
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • FTEK Pollution Control Equipment
  • Sector
  • MGNX Health Care
  • FTEK Industrials
  • Exchange
  • MGNX Nasdaq
  • FTEK Nasdaq
  • Market Cap
  • MGNX 99.7M
  • FTEK 98.7M
  • IPO Year
  • MGNX 2013
  • FTEK N/A
  • Fundamental
  • Price
  • MGNX $1.50
  • FTEK $2.00
  • Analyst Decision
  • MGNX Hold
  • FTEK Strong Buy
  • Analyst Count
  • MGNX 6
  • FTEK 1
  • Target Price
  • MGNX $3.20
  • FTEK $4.00
  • AVG Volume (30 Days)
  • MGNX 828.6K
  • FTEK 253.0K
  • Earning Date
  • MGNX 11-04-2025
  • FTEK 11-04-2025
  • Dividend Yield
  • MGNX N/A
  • FTEK N/A
  • EPS Growth
  • MGNX N/A
  • FTEK N/A
  • EPS
  • MGNX N/A
  • FTEK N/A
  • Revenue
  • MGNX $165,495,000.00
  • FTEK $24,713,000.00
  • Revenue This Year
  • MGNX N/A
  • FTEK $17.16
  • Revenue Next Year
  • MGNX N/A
  • FTEK $15.00
  • P/E Ratio
  • MGNX N/A
  • FTEK N/A
  • Revenue Growth
  • MGNX 303.47
  • FTEK N/A
  • 52 Week Low
  • MGNX $0.99
  • FTEK $0.87
  • 52 Week High
  • MGNX $4.39
  • FTEK $3.65
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 43.25
  • FTEK 25.60
  • Support Level
  • MGNX $1.30
  • FTEK $1.82
  • Resistance Level
  • MGNX $1.69
  • FTEK $2.23
  • Average True Range (ATR)
  • MGNX 0.11
  • FTEK 0.21
  • MACD
  • MGNX -0.02
  • FTEK -0.07
  • Stochastic Oscillator
  • MGNX 31.01
  • FTEK 14.42

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About FTEK Fuel Tech Inc.

Fuel Tech Inc is an technology provider of boiler optimization, efficiency improvement, and air pollution reduction to utility and industrial customers. The company operates in two segments, Air Pollution Control and Fuel Chem. The Air Pollution Control technology segment includes technologies to reduce NOx emissions in flue gas from boilers, incinerators, furnaces and other stationary combustion sources. The Fuel Chem technology segment uses chemical processes in combination with Computational Fluid Dynamics and Chemical Kinetics Modeling boiler modeling for the control of slagging, fouling, corrosion, opacity and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology.

Share on Social Networks: